Analysts estimate that Krystal Biotech will report an earnings per share (EPS) of $1.29.
Krystal Biotech bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Earnings History Snapshot
Last quarter the company missed EPS by $0.32, which was followed by a 1.91% drop in the share price the next day.
Here's a look at Krystal Biotech's past performance and the resulting price change:
Quarter
Q1 2025
Q4 2024
Q3 2024
Q2 2024
EPS Estimate
1.52
1.29
0.90
0.62
EPS Actual
1.20
1.52
0.91
0.94
Price Change %
-2.0%
4.0%
2.0%
-1.0%
Market Performance of Krystal Biotech's Stock
Shares of Krystal Biotech were trading at $153.87 as of July 31. Over the last 52-week period, shares are down 12.3%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.
Analyst Opinions on Krystal Biotech
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Krystal Biotech.
The ...
